Home › NDC Lookup › Ingredients › Lidocaine Hydrochloride › 71351-0021-10
Lidocaine Hydrochloride 10 mg/mL Solution — NDC 71351-0021-10 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NDC 71351-0021-10: Lidocaine Hydrochloride 10 mg/mL Solution

by Brookfield Pharmaceuticals, LLC. · 10 VIAL in 1 BOX / 5 mL in 1 VIAL
Inner NDC 71351-021-05 on each vial (5 mL) inside this package 11-digit 71351-0021-05

This is a package of Lidocaine Hydrochloride 10 mg/mL Solution from Brookfield Pharmaceuticals, LLC., first listed with the FDA Oct 2022 and currently FDA-listed; retail pharmacies pay about $0.4278 per mL (NADAC).

🏷️ FDA NDC (as labeled) 71351-021-10 billing pads the product segment with a zero
This package
Contains5 mL in 1 vial Cost per mL$0.4278 NADAC Per package$21.39 / 50 ml Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.7471/unit — full pricing hub ↓
Rx only Generic FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 71351-021-10 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
71351 labeler · 021 product · 10 package
Package marketed since
Oct 31, 2022
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC)
0371351026255, 0371351021250, 0371351023254, 0371351027252 +5 more
Medicaid fills, this package
277 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026
🚨
Active recall for this product.
Class II · Apr 2, 2026 — Lack of Assurance of Sterility (Huons Co., Ltd.) · FDA recall D-0529-2026
Lots / codes: All lots within expiry · reported Apr 22, 2026
Class II · Apr 2, 2026 — Lack of Assurance of Sterility (Huons Co., Ltd.) · FDA recall D-0532-2026
Lots / codes: All lots within expiry · reported Apr 22, 2026
Check your lot/expiration against the official notice — look up the recall number in the FDA recall database ↗
⚠️
Other active recalls for Lidocaine Hydrochloride (different manufacturers) — 4 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Jul 16, 2026 — Presence of Particulate Matter: Hair was found in products (Fresenius Kabi USA, LLC) · FDA recall D-0726-2026
Class II · Jun 8, 2026 — Lack of Assurance of Sterility (Asclemed USA Inc.) · FDA recall D-0658-2026
Class II · Nov 30, 2021 — Superpotent Drug: Minimally superpotent (Teligent Pharma, Inc.) · FDA recall D-0296-2022
Class I · Nov 30, 2021 — Superpotent Drug (Teligent Pharma, Inc.) · FDA recall D-0295-2022
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 71351-021-10
Product NDC 71351-021
11-digit billing NDC 71351002110
NCPDP billing unit ML — per mL (volume)
UNII V13007Z41A
UPC 0371351026255, 0371351021250, 0371351023254, 0371351027252 +5 more
Application # ANDA212821
SPL Set ID e824ba5b-3289-5ad4-e053-2995a90acc20
Established class (EPC) Amide Local Anesthetic; Antiarrhythmic
Physiologic effect Local Anesthesia
Chemical class Amides
DEA schedule Non-controlled
Marketing category ANDA
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 2022-10-31
Route INTRAVENOUS
Dosage form SOLUTION
Substance LIDOCAINE HYDROCHLORIDE
TE code (Orange Book) AP · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 060675
GCN 26886
HICL code 033592
Ingredient (HICL) Lidocaine Hcl/Pf
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H0
Therapeutic class — intermediate (HIC2) Act On Non-Autonomic Nervous System
HIC3 code H0A
Therapeutic class — specific (HIC3) Local Anesthetics
AHFS code 24:04.04.08
AHFS class Class Ib Antiarrhythmics
FDB label name LIDOCAINE HCL 1% 50 MG/5 ML VL
FDB brand name Lidocaine Hcl
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 060675
  • GCN: 26886
  • HICL (First Databank): 033592
  • AHFS class code: 24:04.04.08
  • RxCUI (RxNorm): 1010033
Why two NDCs? The FDA registers this code as 71351-021-10 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 71351-0021-10. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Antiarrhythmic class.

Pharmacologic class Antiarrhythmic, Amide Local Anesthetic
Drug family (ATC) Antiarrhythmics, class Ib, Local anesthetics, Anesthetics for topical use
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name LIDOCAINE HCL 1% 50 MG/5 ML VL Ingredient Lidocaine Hcl/Pf
📖 What it is MedlinePlus · NLM

Lidocaine injection is used to treat arrhythmias (irregular heartbeats). Lidocaine injection is in a class of medications called antiarrhythmics. It works by acting on the heart muscle to improve the heart's rhythm.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Lidocaine numbs the area where it's applied or injected. Depending on the product, it's used for nerve pain after shingles, minor pain, itching, burns and insect bites, mouth and t...
  • Numbness generally starts within about 20 seconds to 1 minute and lasts roughly 5 to 30 minutes. Some products, such as Hilook Blue Gel Anesthetic, list a 15 to 30 minute wait. The...
  • Mild reactions include dizziness, drowsiness, nervousness and a brief burning at a patch site. Call for help if you have ringing in the ears, a metallic taste, confusion, twitching...
  • Better not to. The toxic effects of local anesthetics add together, and patch labels say not to use them with other topical pain relievers or more than one patch at a time. Ask me...
📖 Read our full Lidocaine guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.428 $21.39 / 50 ml
Medicaid paysCMS SDUD · 12 mo $0.7471 $37.36 / 50 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Feb 2024 Aug 2024 Jan 2025 Jun 2025 $0.464 $0.428
Flat over the last 16 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
71351-0021-10 You're viewing this 10 VIAL in 1 BOX / 5 mL in 1 VIAL Inner NDC 71351-021-05 · each vial (5 mL) $0.4278 / mL $21.39 2022-10-31 — Active
71351-0021-25 71351-021-25 Main listing 25 VIAL in 1 BOX / 5 mL in 1 VIAL Inner NDC 71351-021-05 · each vial (5 mL) $0.3810 / mL $47.62 2022-10-31 — Active

Per mL, this pack runs about 12% above the cheapest pack (NDC 71351-0021-25, $0.3810 vs $0.4278 NADAC).

This pack accounts for about 20% of this product's recent Medicaid fills; most go to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 10 vial in 1 box / 5 ml in 1 vial.
What NDC number is used to bill for this package of Lidocaine Hydrochloride 10 mg/mL Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Lidocaine Hydrochloride 10 mg/mL 63739-0170-24 McKesson 10 vials $0.333 AP Discontinued save 22%
Lidocaine Hydrochloride 10 mg/mL 31722-0117-31 Camber 25 vials $0.371 AP Availability likely save 13%
Lidocaine Hydrochloride 10 mg/mL 55150-0162-05 Eugia 10 vials $0.371 AP Availability likely save 13%
lidocaine hydrochloride 10 mg/mL 83634-0653-02 Avenacy, 25 vials $0.371 AP Availability likely save 13%
Lidocaine Hydrochloride 10 mg/mL 00143-9595-25 Hikma 25 vials $0.381 AP FDA listed save 11%
Lidocaine Hydrochloride 10 mg/mL 72572-0370-25 Civica, 25 vials $0.381 AP FDA listed save 11%
Lidocaine Hydrochloride 10 mg/mLthis 71351-0021-10 Brookfield 10 vials $0.428 AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 00264-9376-88 B. 5 ampules — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 00409-4713-02 Hospira, 5 cellos — AP FDA listed —
LIDOCAINE HCl 10 mg/mL 51662-1438-01 HF 5 ml — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 51662-1651-01 HF 5 ml — AP FDA listed —
Xylocaine Mpf 10 mg/mL 51662-1654-01 HF 5 ml — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 55150-0159-74 Eugia 10 ampules — — FDA listed —
Xylocaine MPF 10 mg/mL 63323-0492-16 Fresenius 25 vials — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 65282-1605-01 Spectra 25 ampules — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 70756-0641-10 Lifestar 10 vials — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 71872-7190-01 Medical 1 ampule — — FDA listed —
Lidocaine Hydrochloride 10 mg/mL 73293-0001-02 Huons 10 vials — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 76420-0080-05 Asclemed 5 ml — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 83854-0011-25 Anthea 25 vials — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 84769-0001-02 Novagenix 10 vials — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 85766-0187-25 Sportpharm 25 ampules — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 85766-0211-05 Sportpharm 10 vials — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 71872-7160-01 Medical 1 syringe — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 71872-7361-01 Medical 1 syringe — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 73293-0004-02 Huons 10 vials — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 00409-9137-05 Hospira, 1 syringe — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 84549-0137-05 ProPharma 5 ml — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 71351-0026-25 Brookfield 25 vials — AP FDA listed —
Lidocaine Hydrochloride 10 mg/mL 00404-9889-05 Henry 1 syringe — AP FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2022
Listed with the FDA since
Oct 2022
📍
2026
Currently FDA-listed
4 years listed
🔓
·
This is a generic
listed with the FDA
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Lidocaine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII QTT17582CB
    A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
  • UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

4 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerBrookfield Pharmaceuticals, LLC.
Application holderHUONS CO LTD
FDA applicationANDA212821 (ANDA)
Labeler code71351
First marketedOct 2022
Product typeHuman Prescription Drug
Portfolio5 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 73 words ▾

1 INDICATIONS AND USAGE Lidocaine Hydrochloride Injection, USP is indicated in adult and pediatric patients for the production of local or regional anesthesia or analgesia for surgery, dental, and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations of Lidocaine Hydrochloride Injection, USP is recommended for each type of block indicated to produce local or regional anesthesia or analgesia [see Dosage and Administration ( 2.2 )] .

⏱️ Dosage and Administration ~3 min read ▾

2 DOSAGE AND ADMINISTRATION

2.1Important Dosage and Administration Information Lidocaine Hydrochloride Injection, USP is not recommended for intrathecal use. Avoid use of Lidocaine Hydrochloride Injection, USP solutions containing antimicrobial preservatives (i.e., multiple-dose vials) for epidural or caudal anesthesia [see Warnings and Precautions ( 5.3 )] . Discard unused portions of solution not containing preservatives, i.e., those supplied in single-dose vials, following initial use.

Visually inspect this product for particulate matter and discoloration prior to administration whenever solution and container permit. Lidocaine Hydrochloride Injection, USP are clear, colorless solutions. Do not administer solutions which are discolored or contain particulate matter.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever the solution and container permit. Solutions which are discolored (e.g., pinkish or darker than slightly yellow) or which contain particulate matter or precipitate should not be administered. Mixing or the prior or intercurrent use of any other local anesthetic with Lidocaine Hydrochloride Injection, USP is not recommended because of insufficient data on the clinical use of such mixtures.

Administration Precautions Lidocaine Hydrochloride Injection, USP is to be administered in carefully adjusted dosages by or under the supervision of experienced clinicians who are well versed in the diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed. Use Lidocaine Hydrochloride Injection, USP only if the following are immediately available: oxygen, cardiopulmonary resuscitative equipment and drugs, and the personnel resources needed for proper management of toxic reactions and related emergencies [see Warnings and Precautions ( 5.1 ), Adverse Reactions ( 6 ), Overdosage ( 10 )] .

The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects related to local anesthetic systemic toxicity when additional local anesthetics are administered with Lidocaine Hydrochloride Injection, USP [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 ), Overdosage ( 10 )]. Aspirate for blood or cerebrospinal fluid (where applicable) prior to injecting Lidocaine Hydrochloride Injection, USP, both the initial dose and all subsequent doses, to avoid intravascular or intrathecal injection.

However, a negative aspiration for blood or cerebrospinal fluid does not ensure against an intravascular or intrathecal injection [see Warnings and Precautions ( 5.7 )] . Avoid rapid injection of a large volume of Lidocaine Hydrochloride Injection, USP and use fractional (incremental) doses when feasible. During major regional nerve blocks, such as those of the brachial plexus or lower extremity, the patient should have an indwelling intravenous catheter to assure adequate intravenous access.

The lowest dosage of Lidocaine Hydrochloride Injection, USP that results in effective anesthesia should be used to avoid high plasma levels and serious adverse reactions. Perform careful and constant monitoring of cardiovascular and respiratory (adequacy of oxygenation and ventilation) vital signs and the patient’s level of consciousness after each local anesthetic injection. Use Lidocaine Hydrochloride Injection, USP in carefully restricted quantities in areas of the body supplied by end arteries or having otherwise compromised blood supply such as digits, nose, external ear, or penis [see Warnings and Precautions ( 5.10 )] .

2.2Recommended Dosages of Lidocaine Hydrochloride Injection, USP in Adults The dosage of Lidocaine Hydrochloride Injection, USP administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the… [Excerpted — this section continues on DailyMed.]

💊 Dosage Forms and Strengths 84 words ▾

3 DOSAGE FORMS AND STRENGTHS Lidocaine Hydrochloride Injection, USP is a clear, colorless solution available as: 1% (200 mg per 20 mL) (10 mg per mL), 20 mL multiple-dose vials 2% (400 mg per 20 mL) (20 mg per mL), 20 mL multiple-dose vials Lidocaine Hydrochloride Injection, USP-Methylparaben Free is a clear, colorless solution available as: 1% (50 mg per 5 mL) (10 mg per mL), 5 mL single-dose vials 2% (100 mg per 5 mL) (20 mg per mL), 5 mL single-dose vials

⛔ Contraindications 33 words ▾

4 CONTRAINDICATIONS Lidocaine Hydrochloride Injection, USP are contraindicated in patients with a known hypersensitivity to lidocaine or to any local anesthetics of the amide-type or to other components of Lidocaine Hydrochloride Injection, USP.

⚠️ Warnings and Cautions ~2 min read ▾

5 WARNINGS AND PRECAUTIONS

5.1Dose-Related Toxicity The safety and effectiveness of Lidocaine Hydrochloride Injection, USP depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies. Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient’s state of consciousness should be performed after injection of Lidocaine Hydrochloride Injection, USP solutions. Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness.

Delay in proper management of dose-related toxicity, underventilation from any cause, and/or altered sensitivity may lead to the development of acidosis, cardiac arrest, and possibly, death. During major regional nerve blocks, such as those of the brachial plexus or lower extremity, the patient should have an indwelling intravenous catheter to assure adequate intravenous access. Use the lowest dosage of Lidocaine Hydrochloride Injection, USP that results in effective anesthesia to avoid high plasma levels and serious adverse effects.

Avoid rapid injection of a large volume of Lidocaine Hydrochloride Injection, USP solution and administer fractional (incremental) doses when feasible. Injection of repeated doses of Lidocaine Hydrochloride Injection, USP may cause significant increases in plasma levels with each repeated dose due to slow accumulation of the drug or its metabolites, or to slow metabolic degradation. Tolerance to elevated blood levels varies with the status of the patient.

Debilitated, elderly patients and acutely ill patients should be given reduced doses commensurate with their age and physical status.

5.2Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition [see Drug Interactions ( 7.5 )] . If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.

Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by a cyanotic skin discoloration and abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue Lidocaine Hydrochloride Injection, USP and any other oxidizing agents.

Depending on the severity of the symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. More severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.

5.3Antimicrobial Preservatives in Multiple-Dose Vials Avoid use of Lidocaine Hydrochloride Injection, USP solutions containing antimicrobial preservatives (i.e., those supplied in multiple-dose vials) for epidural or caudal anesthesia because safety has not been established with such use.

5.4Chondrolysis with Intra-Articular Infusion Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of chondrolysis in patients receiving such infusions. The majority of reported cases of chondrolysis have involved the shoulder joint; cases of gleno-humeral chondrolysis have been described in pediatric and adult patients following intra-articular infusions of local anesthe… [Excerpted — this section continues on DailyMed.]

🤒 Adverse Reactions ~3 min read ▾

6 ADVERSE REACTIONS The following clinically significant adverse reactions have been reported and described in the Warnings and Precautions of the labeling: Dose-Related Toxicity [see Warnings and Precautions ( 5.1 )] Methemoglobinemia [see Warnings and Precautions ( 5.2 )] Chondrolysis with Intra-Articular Infusion [see Warnings and Precautions ( 5.4 )] Severe, Persistent Hypertension, Cerebrovascular Accidents, and Bradycardia Due to Drug Interactions [see Warnings and Precautions ( 5.5 )] Allergic-Type Reactions [see Warnings and Precautions ( 5.6 )] Systemic Toxicities with Unintended Intravascular or Intrathecal Injection [see Warnings and Precautions ( 5.7 )] Respiratory Arrest Following Retrobulbar Block [see Warnings and Precautions ( 5.14 )] The following adverse reactions from voluntary reports or clinical studies have been reported with lidocaine or lidocaine and epinephrine.

Because many of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions to Lidocaine Hydrochloride Injection, USP are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, unintentional intravascular injection, or slow metabolic degradation.

The most commonly encountered acute adverse reactions that demand immediate counter measures were related to the CNS and the cardiovascular system. These adverse reactions were generally dose-related and due to high plasma levels which may have resulted from overdosage, rapid absorption from the injection site, diminished tolerance, or from unintentional intravascular injection of the local anesthetic solution. In addition to systemic does-related toxicity, unintentional intrathecal injection of drug during the intended performance of caudal or lumbar epidural block or nerve blocks near the vertebral column (especially in the head and neck region) has resulted in underventilation or apnea (“Total or High Spinal”).

Also, hypertension due to loss of sympathetic tone and respiratory paralysis or underventilation due to cephalad extension of the motor level of anesthesia have occurred. This has led to secondary cardiac arrest when untreated. When used for dental injections, paresthesia of the lips, tongue, and oral tissues have been reported.

Persistent paresthesia lasting weeks to months and, in some instances, lasting greater than one year, have also been reported. Nervous System Disorders Adverse reactions were characterized by excitation and/or depression of the central nervous system and included lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The incidences of adverse reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration and the physical status of the patient.

In a prospective review of 10,440 patients who received lidocaine hydrochloride for spinal anesthesia, the incidences of adverse reactions were reported to be about 3 percent each for positional headaches, hypotension and backache; 2 percent for shivering; and less than 1 percent each for peripheral nerve symptoms, nausea, respiratory inadequacy and double vision. Persistent motor, sensory and/or autonomic (sphincter control) deficit of some lower spinal segments with slow recovery (several months) or incomplete recovery have been reported in rare instances when caudal or lumbar epidural block has been attempted.

Backache and headache have also been noted following use of these anesthetic procedures. There… [Excerpted — this section continues on DailyMed.]

🔄 Drug Interactions ~2 min read ▾

7 DRUG INTERACTIONS

7.1Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with Lidocaine Hydrochloride Injection, USP cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity [see Warnings and Precautions ( 5.1 )] .

7.2Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration of Lidocaine Hydrochloride Injection, USP with Epinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situation when concurrent therapy is necessary, careful monitoring of the patient’s hemodynamic status is essential [see Warnings and Precautions ( 5.5 )] .

7.3Ergot-Type Oxytocic Drugs Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. Avoid use of Lidocaine Hydrochloride Injection, USP with Epinephrine concomitantly with ergot-type oxytocic drugs [see Warnings and Precautions ( 5.5 )] .

7.4Nonselective Beta-Adrenergic Antagonists Administration of Lidocaine Hydrochloride Injection, USP with Epinephrine in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential [see Warnings and Precautions ( 5.5 )] .

7.5Drugs Associated with Methemoglobinemia Patients that are administered local anesthetics may be at increased risk of developing methemoglobinemia when concurrently exposed to the following oxidizing agents: Class Examples Nitrates/Nitrites nitroglycerin, nitroprusside, nitric oxide, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, rasburicase, ifosfamide, hydroxyurea Antibiotics dapsone, sulfonamides, nitrofurantoin, para- aminosalicylic acid Antimalarials chloroquine, primaquine Anticonvulsants phenytoin, sodium valproate, phenobarbital Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine

7.6Potent Inhalation Anesthetics Serious dose-related cardiac arrhythmias may occur if preparations containing epinephrine (e.g., Lidocaine Hydrochloride Injection, USP with Epinephrine) are used in patients during or following the administration of potent inhalation anesthetics [see Warnings and Precautions ( 5.11 )] .

7.7Phenothiazines and Butyrophenones Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. Concurrent use of Lidocaine Hydrochloride Injection, USP with Epinephrine and these agents should generally be avoided. In situation when concurrent therapy is necessary, careful patient monitoring is essential.

👥 Use in Specific Populations ~3 min read ▾

8 USE IN SPECIFIC POPULATIONS

8.1Pregnancy Risk Summary Available published data and decades of clinical use with Lidocaine Hydrochloride Injection, USP in pregnant women have not identified any drug- associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Local anesthetics may cause varying degrees of toxicity to the mother and fetus and adverse reactions include alterations of the central nervous system, peripheral vascular tone and cardiac function (see Clinical Considerations) . In a published animal reproduction study, pregnant rats administered lidocaine by continuous subcutaneous infusion at a dose approximately 9.6 times the maximum recommended human dose (MRHD) of 500 mg in Lidocaine Hydrochloride Injection, USP during the period of organogenesis resulted in lower fetal body weights [see Data] .

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the United States general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15%to 20%, respectively.

Clinical Considerations Maternal Adverse Reactions Maternal hypotension has resulted from regional anesthesia. Local anesthetics produce vasodilation by blocking sympathetic nerves. Therefore, during treatment of systemic toxicity, maternal hypotension or fetal bradycardia following regional block, the parturient should be maintained in the left lateral decubitus position if possible or manual displacement of the uterus off the great vessels be accomplished.

Elevating the patient’s legs will also help prevent decreases in blood pressure. The fetal heart rate also should be monitored continuously, and electronic fetal monitoring is highly advisable. Labor or delivery Local anesthetics rapidly cross the placenta, and when used for epidural, paracervical, pudendal or caudal block anesthesia, can cause varying degrees of maternal, fetal and neonatal toxicity [see Clinical Pharmacology ( 12.3 )] .

The incidence and degree of toxicity depend upon the procedure performed, the type and amount of drug used, and the technique of drug administration. Adverse reactions in the parturient, fetus and neonate involve alterations of the central nervous system, peripheral vascular tone and cardiac function. However, dosage recommendations for spinal anesthesia are much lower than dosage recommendations for other major blocks.

Spinal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts. Spinal anesthesia has also been reported to prolong the second stage of labor by removing the parturient’s reflex urge to bear down or by interfering with motor function. The use of obstetrical anesthesia may increase the need for forceps assistance.

The use of some local anesthetic drug products during labor and delivery may be followed by diminished muscle strength and tone for the first day or two of life. Data Animal Data Reproduction studies have been performed in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine hydrochloride. In a published study, lidocaine administered to pregnant rats by continuous subcutaneous infusion during the period of organogenesis at 100, 250, and 500 mg/kg/day, did not produce any structural abnormalities, but did result in lower fetal weights at 500 mg/kg/day dose (approximately 9.6 times the maximum recommended human dose [MRHD] of 500 mg lidocaine on a mg/m2 basis) in the absence of maternal toxicity.

8.2Lactation Risk Summary Published data report the presence of lidocaine and its metabolites in human milk in low amounts, along with poor oral bioavailability. There are no data on the effect of lidocaine on the breastfed infant or the effect on milk production. The develop… [Excerpted — this section continues on DailyMed.]

🤰 Pregnancy ~2 min read ▾

8.1Pregnancy Risk Summary Available published data and decades of clinical use with Lidocaine Hydrochloride Injection, USP in pregnant women have not identified any drug- associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Local anesthetics may cause varying degrees of toxicity to the mother and fetus and adverse reactions include alterations of the central nervous system, peripheral vascular tone and cardiac function (see Clinical Considerations) . In a published animal reproduction study, pregnant rats administered lidocaine by continuous subcutaneous infusion at a dose approximately 9.6 times the maximum recommended human dose (MRHD) of 500 mg in Lidocaine Hydrochloride Injection, USP during the period of organogenesis resulted in lower fetal body weights [see Data] .

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the United States general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15%to 20%, respectively.

Clinical Considerations Maternal Adverse Reactions Maternal hypotension has resulted from regional anesthesia. Local anesthetics produce vasodilation by blocking sympathetic nerves. Therefore, during treatment of systemic toxicity, maternal hypotension or fetal bradycardia following regional block, the parturient should be maintained in the left lateral decubitus position if possible or manual displacement of the uterus off the great vessels be accomplished.

Elevating the patient’s legs will also help prevent decreases in blood pressure. The fetal heart rate also should be monitored continuously, and electronic fetal monitoring is highly advisable. Labor or delivery Local anesthetics rapidly cross the placenta, and when used for epidural, paracervical, pudendal or caudal block anesthesia, can cause varying degrees of maternal, fetal and neonatal toxicity [see Clinical Pharmacology ( 12.3 )] .

The incidence and degree of toxicity depend upon the procedure performed, the type and amount of drug used, and the technique of drug administration. Adverse reactions in the parturient, fetus and neonate involve alterations of the central nervous system, peripheral vascular tone and cardiac function. However, dosage recommendations for spinal anesthesia are much lower than dosage recommendations for other major blocks.

Spinal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts. Spinal anesthesia has also been reported to prolong the second stage of labor by removing the parturient’s reflex urge to bear down or by interfering with motor function. The use of obstetrical anesthesia may increase the need for forceps assistance.

The use of some local anesthetic drug products during labor and delivery may be followed by diminished muscle strength and tone for the first day or two of life. Data Animal Data Reproduction studies have been performed in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine hydrochloride. In a published study, lidocaine administered to pregnant rats by continuous subcutaneous infusion during the period of organogenesis at 100, 250, and 500 mg/kg/day, did not produce any structural abnormalities, but did result in lower fetal weights at 500 mg/kg/day dose (approximately 9.6 times the maximum recommended human dose [MRHD] of 500 mg lidocaine on a mg/m2 basis) in the absence of maternal toxicity.

🧒 Pediatric Use 25 words ▾

8.4Pediatric Use Dosages in children should be reduced, commensurate with age, body weight and physical condition [see Dosage and Administration ( 2.6 )] .

🧓 Geriatric Use 25 words ▾

8.5Geriatric Use Elderly patients should be given reduced doses commensurate with their age and physical condition. [see Dosage and Administration ( 2.6 )] .

🆘 Overdosage ~2 min read ▾

10 OVERDOSAGE Clinical Presentation Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution [see Warnings and Precautions ( 5.1 ) and see Adverse Reactions ( 6 )] . Management The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient’s state of consciousness after each local anesthetic injection.

At the first sign of change, oxygen should be administered. The first step in the management of convulsions, as well as underventilation or apnea due to unintended subarachnoid injection of drug solution, consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask. Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated, keeping in mind that drugs used to treat convulsions sometimes depress the circulation when administered intravenously.

Should convulsions persist despite adequate respiratory support, and if the status of the circulation permits, a benzodiazepine (such as diazepam) may be administered intravenously. The clinician should be familiar, prior to the use of local anesthetics, with these anticonvulsant drugs. Supportive treatment of circulatory depression may require administration of intravenous fluids and, when appropriate, a vasopressor as directed by the clinical situation (e.g., ephedrine).

If not treated immediately, both convulsions and cardiovascular depression can result in hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest. Underventilation or apnea due to unintentional subarachnoid injection of local anesthetic solution may produce these same signs and also lead to cardiac arrest if ventilatory support is not instituted. If cardiac arrest should occur, standard cardiopulmonary resuscitative measures should be instituted.

Endotracheal intubation, employing drugs and techniques familiar to the clinician, may be indicated, after initial administration of oxygen by mask, if difficulty is encountered in the maintenance of a patent airway or if prolonged ventilatory support (assisted or controlled) is indicated. Dialysis is of negligible value in the treatment of acute overdosage with lidocaine hydrochloride.

🧬 Clinical Pharmacology ~2 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Lidocaine hydrochloride stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.

12.2Pharmacodynamics Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure. With central neural blockade these changes may be attributable to block of autonomic fibers, a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system, and/or the beta-adrenergic receptor stimulating action of epinephrine when present. The net effect is normally a modest hypotension when the recommended dosages are not exceeded.

Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of lidocaine hydrochloride required to produce overt systemic effects. Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6 mcg free base per mL.

12.3Pharmacokinetics Systemic plasma levels of lidocaine following administration of Lidocaine Hydrochloride Injection, USP do not correlate with local efficacy. Absorption Information derived from diverse formulations, concentrations and usages reveals that lidocaine hydrochloride is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent. Except for intravascular administration, the highest blood levels are obtained following intercostal nerve block and the lowest after subcutaneous administration.

Distribution The plasma binding of lidocaine hydrochloride is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 mcg of free base per mL 60 to 80 percent of lidocaine hydrochloride is protein bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein.

Lidocaine hydrochloride crosses the blood-brain and placental barriers, presumably by passive diffusion. Elimination The elimination half-life of lidocaine hydrochloride following an intravenous bolus injection is typically 1.5 to 2 hours. Metabolism Lidocaine hydrochloride is metabolized rapidly by the liver, and biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation.

N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of lidocaine hydrochloride. Excretion Approximately 90% of lidocaine hydrochloride administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged by the kidneys.

The primary metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline. Specific Populations Patients with Hepatic Impairment Because of the rapid rate at which lidocaine hydrochloride is metabolized, any condition that affects liver function may alter lidocaine HCl kinetics. The half-life may be prolonged two-fold or more in patients with liver dysfunction.

Patients with Renal Impairment Renal dysfunction does not affect lidocaine hydrochloride kinetics but may increase the accumulation of metabolites.

🧬 Mechanism of Action 28 words ▾

12.1Mechanism of Action Lidocaine hydrochloride stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.

📦 How Supplied / Storage and Handling 136 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING Storage : All solutions should be stored at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from light. For single-dose vials: Discard unused portion.

Lidocaine Hydrochloride Injection, USP. This product is clear and colorless. NDC Container Concentration Size Total (mg) 71351-021-10 Single Dose Vial (Package of 10) 1% (10 mg/mL) 5 mL 50 71351-021-25 Single Dose Vial (Package of 25) 1% (10 mg/mL) 5 mL 50 71351-026-25 Multiple Dose Vial (Package of 25) 1% (10 mg/mL) 20 mL 200 71351-023-10 Single Dose Vial (Package of 10) 2% (20 mg/mL) 5 mL 100 71351-023-25 Single Dose Vial (Package of 25) 2% (20 mg/mL) 5 mL 100 71351-027-25 Multiple Dose Vial (Package of 25) 2% (20 mg/mL) 20 mL 400

📋 Description ~1 min read ▾

11 DESCRIPTION: Lidocaine Hydrochloride Injection, USP contains lidocaine hydrochloride, an amide local anesthetic, as the active pharmaceutical ingredient. The route of administration for Lidocaine Hydrochloride Injection, USP is by injection, for infiltration, nerve block, epidural and caudal use. Multiple dose vials contain methylparaben and they should not be used for caudal and lumbar epidural blocks.

Dosage forms listed as Lidocaine Hydrochloride Injection-Methylparaben Free indicate single-dose solutions that are Methylparaben Free (MPF). Lidocaine hydrochloride, is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, monohydrochloride monohydrate and has the molecular weight of 288.8 g/mol. Lidocaine hydrochloride molecular formula is C 14 H 22 N 2 O • HCl•H 2 O, and has the following structural formula: Lidocaine Hydrochloride Injection, USP in multiple dose vials is a sterile, nonpyrogenic, isotonic, clear, colorless solution containing lidocaine hydrochloride and sodium chloride.

Each mL contains 1 mg methylparaben as an antiseptic preservative. The pH of these solutions is adjusted to approximately 6.5 (5.0 to 7.0) with sodium hydroxide and hydrochloric acid. Ingredients Strength 1% 2% Amount (Per mL) Amount (Per mL) Lidocaine Hydrochloride (Anhydrous) 10 mg* 20 mg£ Sodium Chloride 7 mg 6 mg Methylparaben 1 mg 1 mg Sodium Hydroxide Added for pH Adjustment to approximately 6.5 (5.0 to 7.0) Hydrochloric Acid * Quantity is equivalent to 10.7 mg/ mL Lidocaine Hydrochloride, USP (Monohydrate). £ Quantity is equivalent to 21.3 mg/ mL Lidocaine Hydrochloride, USP (Monohydrate).

Lidocaine Hydrochloride Injection, USP-Methylparaben Free is a sterile, nonpyrogenic, isotonic, clear, colorless, and preservative-free solution. The pH of these solutions is adjusted to approximately 6.5 (5.0 to 7.0) with sodium hydroxide and hydrochloric acid. Ingredients Strength 1% 2% Amount (Per mL) Amount (Per mL) Lidocaine Hydrochloride (Anhydrous) 10 mg* 20 mg£ Sodium Chloride 7 mg 6 mg Sodium Hydroxide Added for pH Adjustment to approximately 6.5 (5.0 to 7.0) Hydrochloric Acid figure 1

🧬 Pharmacokinetics ~1 min read ▾

12.3Pharmacokinetics Systemic plasma levels of lidocaine following administration of Lidocaine Hydrochloride Injection, USP do not correlate with local efficacy. Absorption Information derived from diverse formulations, concentrations and usages reveals that lidocaine hydrochloride is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent. Except for intravascular administration, the highest blood levels are obtained following intercostal nerve block and the lowest after subcutaneous administration.

Distribution The plasma binding of lidocaine hydrochloride is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 mcg of free base per mL 60 to 80 percent of lidocaine hydrochloride is protein bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein.

Lidocaine hydrochloride crosses the blood-brain and placental barriers, presumably by passive diffusion. Elimination The elimination half-life of lidocaine hydrochloride following an intravenous bolus injection is typically 1.5 to 2 hours. Metabolism Lidocaine hydrochloride is metabolized rapidly by the liver, and biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation.

N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of lidocaine hydrochloride. Excretion Approximately 90% of lidocaine hydrochloride administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged by the kidneys.

The primary metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline. Specific Populations Patients with Hepatic Impairment Because of the rapid rate at which lidocaine hydrochloride is metabolized, any condition that affects liver function may alter lidocaine HCl kinetics. The half-life may be prolonged two-fold or more in patients with liver dysfunction.

Patients with Renal Impairment Renal dysfunction does not affect lidocaine hydrochloride kinetics but may increase the accumulation of metabolites.

🧬 Pharmacodynamics 116 words ▾

12.2Pharmacodynamics Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure. With central neural blockade these changes may be attributable to block of autonomic fibers, a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system, and/or the beta-adrenergic receptor stimulating action of epinephrine when present. The net effect is normally a modest hypotension when the recommended dosages are not exceeded.

Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of lidocaine hydrochloride required to produce overt systemic effects. Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6 mcg free base per mL.

🧪 Nonclinical Toxicology 103 words ▾

13 NONCLINICAL TOXICOLOGY

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Studies of lidocaine hydrochloride in animals to evaluate the carcinogenic potential have not been conducted. Mutagenesis Studies of lidocaine hydrochloride in animals to evaluate the mutagenic potential have not been conducted. Impairment of Fertility In a published study, female Sprague-Dawley rats were treated subcutaneously with lidocaine via osmotic pumps starting two weeks prior to mating, and reproductive effects were assessed.

Rats dosed up to the high dose of 500 mg/kg/day (approximately 45 times the MRDD on a mg/m2 basis) showed no effects on copulatory rate, pregnancy rate, numbers of corpora lutea, or implantations.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 100 words ▾

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Studies of lidocaine hydrochloride in animals to evaluate the carcinogenic potential have not been conducted. Mutagenesis Studies of lidocaine hydrochloride in animals to evaluate the mutagenic potential have not been conducted. Impairment of Fertility In a published study, female Sprague-Dawley rats were treated subcutaneously with lidocaine via osmotic pumps starting two weeks prior to mating, and reproductive effects were assessed.

Rats dosed up to the high dose of 500 mg/kg/day (approximately 45 times the MRDD on a mg/m2 basis) showed no effects on copulatory rate, pregnancy rate, numbers of corpora lutea, or implantations.

📄 Package Label / Principal Display Panel ~3 min read ▾

50 mg/5mL (10 mg/mL) Carton Label NDC 71351- 021 -25 Rx only Lidocaine HCl Injection, USP 1% 50 mg/5 mL (10 mg/mL) For Infiltration and Nerve Block Including Caudal and Epidural Use. Methylparaben Free 25 x 5 mL Single-Dose Vials Distributed By: Brookfield Pharmaceuticals, LLC Brookfield, WI 53005 Made in S. Korea 50 mg/5mL (10 mg/mL) Carton Label NDC 71351- 021 -10 Rx only Lidocaine HCl Injection, USP 1% 50 mg/5 mL (10 mg/mL) For In filtration and Nerve Block Including Caudal and Epidural Use.

Methylparaben Free 10 x 5 mL Single-Dose Vials Brookfield Pharmaceuticals, LLC Brookfield, WI 53005 Made in S. Korea 50 mg/5mL (10 mg/mL) Vial Label NDC 71351- 021 -05 Lidocaine HCl Injection, USP 1% 50 mg/5 mL (10 mg/mL) For Infiltration and Nerve Block Including Caudal and Epidural Use. Methylparaben Free 5 mL Single Dose Vial Rx only Distributed by: Brookfield Pharmaceuticals, LLC Brookfield, WI 53005 Sterile, nonpyrogenic.

Can be resterilized by autoclaving. Do not use if solution is discolored or contains a precipitate. Store at 20° to 25°C(68° to 77°F) [see USP Controlled Room Temperature].

EL6460-03 EK6145-01 EK6146-02 EL6460-03

100 mg/5mL (20 mg/mL) Carton Label NDC 71351- 023 -25 Rx only Lidocaine HCl Injection, USP 2% 100 mg/5 mL (20 mg/mL) For Infiltration and Nerve Block Including Caudal and Epidural Use. Methylparaben Free 25 x 5 mL Single-Dose Vials Distributed By: Brookfield Pharmaceuticals, LLC Brookfield, WI 53005 Made in S. Korea 100 mg/5mL (20 mg/mL) Carton Label NDC 71351- 023 -10 Rx only Lidocaine HCl Injection, USP 2% 100 mg/5 mL (20 mg/mL) For Infiltration and Nerve Block Including Caudal and Epidural Use.

Methylparaben Free 10 x 5 mL Single-Dose Vials Brookfield Pharmaceuticals, LLC Brookfield, WI 53005 Made in S. Korea 100 mg/5mL (20 mg/mL) Vial Label NDC 71351- 023 -05 Lidocaine HCl Injection, USP 2% 100 mg/5 mL (20 mg/mL) For Infiltration and Nerve Block Including Caudal and Epidural Use. Methylparaben Free 5 mL Single Dose Vial Rx only Distributed by: Brookfield Pharmaceuticals, LLC Brookfield, WI 53005 Sterile, nonpyrogenic.

Can be resterilized by autoclaving. Do not use if solution is discolored or contains a precipitate. Store at 20° to 25°C(68° to 77°F) [see USP Controlled Room Temperature].

EL6558-02 2pct-carton-label-25V (Brookfield) EK6213-02 EL6558-02

200 mg/20mL (10 mg/mL) Carton Label NDC 71351- 026-25 Rx only Lidocaine HCl Injection, USP 1% 200 mg/20 mL (10 mg/mL) For Infiltration and Nerve Block Not for Caudal and Epidural Use. 25 x 20 mL Multiple Dose Vials Distributed By: Brookfield Pharmaceuticals, LLC Brookfield, WI 53005 Made in S. Korea [EK6388-00] 200 mg/20mL (10 mg/mL) Vial Label NDC 71351- 026-20 Lidocaine HCl Injection, USP 1% 200 mg/20 mL (10 mg/mL) For Infiltration and Nerve Block Not for Caudal and Epidural Use.

20 mL Multiple Dose Vial Rx only Distributed by: Brookfield Pharmaceuticals, LLC Brookfield, WI 53005 Sterile, nonpyrogenic. Can be resterilized by autoclaving. Do not use if solution is discolored or contains a precipitate.

Store at 20° to 25°C(68° to 77°F) [see USP Controlled Room Temperature]. [EL6766-00] EK6388-00 EK6766-00

400 mg/20mL (20 mg/mL) Carton Label NDC 71351- 027-25 Rx only Lidocaine HCl Injection, USP 2% 400 mg/20 mL (20 mg/mL) For Infiltration and Nerve Block Not for Caudal and Epidural Use. 25 x 20 mL Multiple Dose Vials Distributed By: Brookfield Pharmaceuticals, LLC Brookfield, WI 53005 Made in S. Korea [EK6389-00] 400 mg/20mL (20 mg/mL) Vial Label NDC 71351- 027-20 Lidocaine HCl Injection, USP 2% 400 mg/20 mL (20 mg/mL) For Infiltration and Nerve Block Not for Caudal and Epidural Use.

20 mL Multiple Dose Vial Rx only Distributed by: Brookfield Pharmaceuticals, LLC Brookfield, WI 53005 Sterile, nonpyrogenic. Can be resterilized by autoclaving. Do not use if solution is discolored or contains a precipitate.

Store at 20° to 25°C(68° to 77°F) [see USP Controlled Room Temperature]. [EL6767-00] EK6389-00 EL6767-00

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q3 2025 · 3 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
277
Units reimbursed last 4 qtrs
2.2K
Gross reimbursed last 4 qtrs
$1.6K
Avg / prescription
$5.82
Avg / unit
$0.7471
Latest quarter Q3 2025
0Rx
Medicaid pays / mL
$0.7471
gross reimbursed
vs
NADAC / mL
$0.4278
acquisition cost
=
Spread
+$0.3193
+75% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
18% FFS 82% MCO
Fee-for-service · 49 Rx Managed care · 228 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 115 units · 0.6 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: 179 units · 2.6 per 100k residents MA California: 759 units · 1.9 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: 245 units · 4.0 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: 859 units · 3.8 per 100k residents FL
Units reimbursed · per 100k residents
0.64.0
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Maryland 4.0 /100k
2 Florida 3.8 /100k
3 Massachusetts 2.6 /100k
4 California 1.9 /100k
5 New York 0.6 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
25 vials71351-0021-25 1,089 Rx · $19,318
Drug total (last 4 qtrs): 1,366 Rx · 25,492 units · $20,929 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Lidocaine Hydrochloride — the ingredient across all brands.

Top reported reactions

Nausea3,852
Pain3,766
Fatigue3,663
Headache3,434
Dyspnoea2,880
Diarrhoea2,600
Pneumonia2,374

Age at onset

Neonate188
Infant89
Child406
Adolescent296
Adult6,288
Elderly3,920

Reporter sex

61,768 reports
Male · 37%
Female · 63%
Unknown · 0%

Serious outcomes

Hospitalization22,449
Death6,206
Life-threatening5,808
Disabling1,659
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 5,910 4,238
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.